|
Bevacizumab Biosimilar IBI305 plus sintilimab Clinical Trials
1 actively recruiting trial
▼ -1 trial since June 2026
Also known as: Byvasda (B) plus S
Top Sponsors
- Ze-yang Ding, MD1
Indications
- Liver Disease1
- Hepatocellular Carcinoma Non-resectable1
- Liver Cancer1
- Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.